Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The effect of dual-release versus conventional hydrocortisone on fatigue, measured by ecological momentary assessments

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Sex differences in acromegaly at diagnosis: A nationwide cohort study and meta-analysis of the literature

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Adrenal insufficiency in kidney transplant patients during low-dose prednisolone therapy: a cross-sectional case-control study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Corticotroph aggressive pituitary tumours and carcinomas frequently harbour ATRX mutations

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Ulla Feldt-Rasmussen
  • Derralynn Hughes
  • Gere Sunder-Plassmann
  • Suma Shankar
  • Khan Nedd
  • Iacopo Olivotto
  • Damara Ortiz
  • Toya Ohashi
  • Takashi Hamazaki
  • Nina Skuban
  • Julie Yu
  • Jay A Barth
  • Kathleen Nicholls
Vis graf over relationer

Results from the 18-month randomized treatment period of the phase 3 ATTRACT study demonstrated the efficacy and safety of oral migalastat compared with enzyme replacement therapy (ERT) in patients with Fabry disease who previously received ERT. Here, we report data from the subsequent 12-month, migalastat-only, open-label extension (OLE) period. ATTRACT (Study AT1001-012; NCT01218659) was a randomized, open-label, active-controlled study in patients aged 16-74 years with Fabry disease, an amenable GLA variant, and an estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2. During the OLE, patients who received migalastat 150 mg every other day (QOD) during the randomized period continued receiving migalastat (Group 1 [MM]); patients who received ERT every other week discontinued ERT and started migalastat treatment (Group 2 [EM]). Outcome measures included eGFR, left ventricular mass index (LVMi), composite clinical outcome (renal, cardiac or cerebrovascular events), and safety. Forty-six patients who completed the randomized treatment period continued into the OLE (Group 1 [MM], n = 31; Group 2 [EM], n = 15). eGFR remained stable in both treatment groups. LVMi decreased from baseline at month 30 in Group 1 (MM) in patients with left ventricular hypertrophy at baseline. Only 10% of patients experienced a new composite clinical event with migalastat treatment during the OLE. No new safety concerns were reported. In conclusion, in patients with Fabry disease and amenable GLA variants, migalastat 150 mg QOD was well tolerated and demonstrated durable, long-term stability of renal function and reduction in LVMi.

OriginalsprogEngelsk
TidsskriftMolecular Genetics and Metabolism
Vol/bind131
Udgave nummer1-2
Sider (fra-til)219-228
Antal sider10
ISSN1096-7192
DOI
StatusUdgivet - 6 okt. 2020

Bibliografisk note

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

ID: 61808067